Allogene Therapeutics, Inc. (ALLO) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Allogene Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.47HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.66HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — ALLO vs PHAT
growth of $100 · dividends reinvested · last 7yALLO -94.9% (-34.5%/yr)PHAT -72.8% (-17.0%/yr)PHAT compounded faster over this window
Log scale — wide-divergence pair
ALLO PHAT
ALLO vs PHAT: by the numbers
- •PHAT is the larger company ($539M vs $507M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -3566.68% net margin).
Metrics side by side
Valuation
| Metric | ALLO | PHAT |
|---|---|---|
| P/S ratio | 109.35 | 2.25 |
| P/B ratio | 1.16 | N/A |
Profitability
| Metric | ALLO | PHAT |
|---|---|---|
| Gross margin | 0.00% | 82.92% |
| Operating margin | 0.00% | -91.36% |
| Net margin | -3566.68% | -41.34% |
| ROE | -37.94% | N/A |
| ROIC | -34.79% | -23.45% |
Growth (annualized)
| Metric | ALLO | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | N/A |
| Total return CAGR (5Y) | -42.72% | -26.93% |
Frequently asked
- How have ALLO and PHAT total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.